Free Trial
NYSE:BAX

Baxter International Q2 2025 Earnings Report

Baxter International logo
$28.71 -0.99 (-3.33%)
Closing price 07/11/2025 03:59 PM Eastern
Extended Trading
$28.68 -0.03 (-0.09%)
As of 07:05 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Baxter International EPS Results

Actual EPS
N/A
Consensus EPS
$0.60
Beat/Miss
N/A
One Year Ago EPS
N/A

Baxter International Revenue Results

Actual Revenue
N/A
Expected Revenue
$2.82 billion
Beat/Miss
N/A
YoY Revenue Growth
N/A

Baxter International Announcement Details

Quarter
Q2 2025
Time
Before Market Opens
Conference Call Date
Tuesday, August 5, 2025
Conference Call Time
8:30AM ET

Conference Call Resources

Baxter International Earnings Headlines

Citigroup Cuts Baxter International (NYSE:BAX) Price Target to $32.00
This Signal Only Flashes Once Every 4 Years – And It Just Triggered
This same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in crypto. Now it’s back, and the smart money is already positioning. A free training reveals the step-by-step strategy and altcoin picks designed to help you capitalize on the next wave.
See More Baxter International Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Baxter International? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Baxter International and other key companies, straight to your email.

About Baxter International

Baxter International (NYSE:BAX) (NYSE: BAX) is a global medical products company dedicated to saving and sustaining lives. Founded in 1931 by Dr. Ralph Stephens and Dr. Donald Baxter, the company initially focused on intravenous solutions and has since expanded its offerings to include a broad array of products and therapies. Baxter operates through two primary business segments: Hospital Products, which provides infusion systems, parenteral nutrition, and surgical care products; and Kidney Care, delivering dialysis equipment, related disposables, and renal pharmaceuticals.

Today, Baxter’s portfolio encompasses advanced drug delivery systems, biosurgery products, nutritional therapies, and renal care technologies. Its infusion systems facilitate precise delivery of critical medications in hospitals and outpatient settings, while its biosurgery division offers hemostats, sealants, and tissue repair solutions. In kidney care, Baxter supplies hemodialysis and peritoneal dialysis equipment along with dialysis-related disposables and therapies that serve patients with chronic kidney disease at home and in clinical environments.

Headquartered in Deerfield, Illinois, Baxter maintains operations in more than 100 countries across North America, Europe, Latin America, Asia-Pacific, and the Middle East. Under the leadership of Chairman and Chief Executive Officer José E. Almeida, the company emphasizes innovation, operational excellence, and patient-centric solutions. Baxter’s extensive global reach, combined with its commitment to research and development, positions it as a key partner for healthcare providers seeking reliable and effective medical technologies.

View Baxter International Profile

More Earnings Resources from MarketBeat